Solid Biosciences Inc. (SLDB)

NASDAQ: SLDB · USD

$6.47

+0.28 (+4.5%)· Recorded snapshot

Market cap	693.7M
Net income (ttm)	-207.1M
EPS (ttm)	-$1.87
Shares out	107.2M
Volume	1,345,544
Beta	2.47

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -207.1M
EPS (ttm): -$1.87
Market cap: 693.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-65.5

P25 -113.8P50 -46.5P75 -0.9

ROIC-39.3

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All SLDB indicators

Market & fundamental data

Available fields

180

Groups with data

Currency

USD

Showing 180 of 180 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001707502
Company name	Solid Biosciences Inc.
Country	United States
Country code	US
CUSIP number	83422E204
Earnings date	2026-11-10
Earnings time	amc
Employees	121
Employees change	21
Employees growth	21%
Enterprise value	$336.2M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2013
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2018-01-26
Is primary listing	Yes
Is SPAC	No
ISIN number	US83422E2046
Last 10-K release date	2026-03-19
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	2022-10-28
Last stock split type	Reverse
Market cap	$693.7M
Market cap category	Small-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$6.47
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	SLDB
U.S. state	Massachusetts
Website	https://www.solidbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-28.9%
FCF / EV yield	-59.06%
FCF yield	-27.8%
P/B ratio	1.74x
Price / tangible book value	1.81x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.7M
ROA	-36.38%
ROA (5Y)	-35.21%
ROCE	-54.12%
ROE	-65.5%
ROE (5Y)	-68.93%
ROIC	-39.25%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	6
EPS growth years	6
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-965,000
Depreciation and amortization	$1.6M
EBIT	$-212.2M
EBITDA	$-210.5M
EPS	$-1.87
FCF per share	$-1.75
Financing cash flow	$293.8M
Free cash flow	$-187.8M
Free cash flow minus SBC	$-209M
Investing cash flow	$-87.1M
Net borrowing	$-446,000
Net cash flow	$19.9M
Net income	$-207.1M
Operating cash flow minus SBC	$-208M
Operating income	$-212.2M
Stock-based compensation	$21.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$3.56
Debt / equity	0.05
Long-term assets	$25.5M
Long-term liabilities	$17.9M
Net cash (debt)	$357.5M
Net cash / market cap	52.93%
Net cash growth	45.89%
Net debt / equity	-0.96
Piotroski F-Score	2
Property, plant and equipment	$24.6M
Shareholders' equity	$374.1M
Tangible book value	$374.1M
Tangible book value per share	$3.56
Total assets	$420.6M
Total cash	$377.7M
Total debt	$20.2M
Total liabilities	$46.5M
WACC	17.32%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$395.1M
Current liabilities	$28.6M
Current ratio	13.82
Net working capital	$-8.9M
Quick ratio	13.21
Working capital	$366.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-80.98%
Dividend yield	0%
Shareholder yield	-80.98%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$8.03
1D price change	4.52%
1M price change	-11.93%
1M total return	-11.93%
1W price change	0.31%
1W total return	0.31%
1Y price change	8.81%
1Y return CAGR	8.82%
1Y total return	8.81%
20-day SMA	$6.34
200-day SMA	$7.65
3M price change	-18.63%
3M total return	-18.63%
3Y price change	239.68%
3Y return CAGR	50.31%
3Y total return	239.68%
50-day SMA	$7.94
50-day SMA vs 200-day SMA	50over200
52-week high	$11.45
52-week high date	2026-07-06
52-week low	$3.79
52-week low date	2025-11-07
5Y price change	-77.94%
5Y return CAGR	-26.09%
5Y total return	-77.94%
6M price change	-14.4%
6M total return	-14.4%
All-time high	$822.60
All-time high date	2018-06-19
All-time low	$1.81
All-time low date	2023-10-30
Average true range (ATR)	$0.45
Average volume	1.4M
Beta (1Y)	1.62
Beta (2Y)	1.86
Beta (5Y)	2.47
Change from 52-week high	-43.49%
Change from 52-week low	70.71%
Change from all-time high	-99.22%
Change from all-time low	254.7%
Change from open	7.48%
Day's gap	-2.75%
Dollar volume	$8.7M
High price	$6.50
Low price	$6.02
Monthly RSI	46.48
Open price	$6.02
Position in 52-week range	93.75%
Premarket change	0.16%
Premarket close	$6.19
Premarket price	$6.20
Previous close	$6.19
Price vs 150-day SMA	-20.06%
Price vs 20-day SMA	1.2%
Price vs 200-day SMA	-16.1%
Price vs 50-day SMA	-19.11%
Relative volume	0.98
RSI	45.13
Sharpe ratio	0.45
Sharpe ratio (3Y)	0.8
Sharpe ratio (5Y)	0.04
Sortino ratio	0.76
Sortino ratio (3Y)	1.45
Sortino ratio (5Y)	0.14
Volume	1.3M
Weekly RSI	43.66
YTD price change	13.83%
YTD total return	13.83%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	64.8M
Float percentage	60.43%
Shares change (QoQ)	30.85%
Shares change (YoY)	80.98%
Shares held by insiders	0.92%
Shares held by institutions	69.84%
Shares outstanding	107.2M
Short % of float	19.64%
Short % of shares	11.87%
Short ratio	10 days

Deeper analysis on SLDB

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this SLDB report

Is a complete SLDB research report available?

No complete published report is available for Solid Biosciences Inc. (SLDB) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Solid Biosciences Inc. (SLDB)

Price

Financial snapshot

Fair-value bridge

Latest news · SLDB

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All SLDB indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on SLDB

Frequently asked questions